ID
IONS icon

Integral Derivatives’s Ionis Pharmaceuticals IONS Stock Holding History

Integral Derivatives’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-33,847
Closed -$1.37M – 986
2015
Q4 		$2.1M Sell
33,847
-2,320
-6% -$125K 0.05% 268
2015
Q3 		$1.46M Buy
36,167
+2,375
+7% +$123K 0.04% 389
2015
Q2 		$1.95M Sell
33,792
-3,161
-9% -$201K 0.05% 327
2015
Q1 		$2.35M Sell
36,953
-7,513
-17% -$510K 0.05% 251
2014
Q4 		$2.75M Sell
44,466
-1,000
-2% -$49.3K 0.05% 329
2014
Q3 		$1.76M Buy
45,466
+13,969
+44% +$495K 0.03% 514
2014
Q2 		$1.08M Buy
+31,497
New +$992K 0.02% 651

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Integral Derivatives's IONS Position: Q1 2016 in Review

Integral Derivatives sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 33,847 shares — an estimated $1.37M sold.

Integral Derivatives first reported a position in IONS in Q2 2014 and held it in 7 quarters. The position peaked at $2.75M in Q4 2014. 315 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

  • Integral Derivatives reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Integral Derivatives sold 33,847 Ionis Pharmaceuticals shares in Q1 2016, an estimated $1.37M.
  • Integral Derivatives first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 7 quarters.
  • Integral Derivatives's Ionis Pharmaceuticals position peaked at $2.75M in Q4 2014.
  • 315 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Integral Derivatives's 13F filing for Q1 2016, filed 12 Apr 2016.